We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

5 hedge funds and large institutions have $48.4K invested in Decoy Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

262% more capital invested

Capital invested by funds: $13.4K → $48.4K (+$35K)

150% more funds holding

Funds holding: 2 → 5 (+3)

0.02% more ownership

Funds ownership: 0% → 0.02% (+0.02%)

Holders
5
Holders Change
+3
Holders Change %
+150%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$43.4K
2
TSS
Two Sigma Securities
New York
+$24.7K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$18.6K
4
TRCT
Tower Research Capital (TRC)
New York
+$5.24K

Top Sellers

No sellers this quarter

DCOY Hedge Fund Activity: Q1 2025 in Review

5 of the 7,470 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q1 2025, worth a combined $48.4K — up 262% from $13.4K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new DCOY positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $43.4K.

  • 5 institutional investors held Decoy Therapeutics (DCOY) as of Q1 2025, up from 2 in Q4 2024.
  • Funds reported $48.4K of Decoy Therapeutics stock for Q1 2025, up 262% quarter-over-quarter.
  • 3 funds opened new Decoy Therapeutics positions in Q1 2025 and 0 closed out, a net change of +3 holders.
  • The largest Decoy Therapeutics buyer in Q1 2025 was UBS Group, an estimated $43.4K added.

Based on aggregated 13F filings for Q1 2025.